0001209191-20-004740.txt : 20200123 0001209191-20-004740.hdr.sgml : 20200123 20200123192218 ACCESSION NUMBER: 0001209191-20-004740 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200121 FILED AS OF DATE: 20200123 DATE AS OF CHANGE: 20200123 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Duncan Jason CENTRAL INDEX KEY: 0001741553 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33451 FILM NUMBER: 20543419 MAIL ADDRESS: STREET 1: C/O ALBIREO PHARMA, INC. STREET 2: 10 POST OFFICE SQUARE, SUITE 502 SOUTH CITY: BOSTON STATE: MA ZIP: 02109 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ALBIREO PHARMA, INC. CENTRAL INDEX KEY: 0001322505 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10 POST OFFICE SQUARE STREET 2: SUITE 502 SOUTH CITY: BOSTON STATE: MA ZIP: 02109 BUSINESS PHONE: 857-415-4774 MAIL ADDRESS: STREET 1: 10 POST OFFICE SQUARE STREET 2: SUITE 502 SOUTH CITY: BOSTON STATE: MA ZIP: 02109 FORMER COMPANY: FORMER CONFORMED NAME: Biodel Inc DATE OF NAME CHANGE: 20050331 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-01-21 0 0001322505 ALBIREO PHARMA, INC. ALBO 0001741553 Duncan Jason C/O ALBIREO PHARMA INC. 10 POST OFFICE SQUARE, SUITE 1000 BOSTON MA 02109 0 1 0 0 Chief Legal Officer and GC Common Stock 2020-01-22 4 S 0 447 23.97 D 4553 D Stock Option (right to buy) 24.67 2020-01-21 4 A 0 31500 0.00 A 2030-01-20 Common Stock 31500 31500 D Shares sold pursuant to a Rule 10b5-1 arrangement to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.95 to $24.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. Represents 803 shares of common stock and 3,750 restricted stock units. This option vests as to 25% of the shares on January 21, 2021, with the remainder vesting in equal installments every three months thereafter beginning on April 21, 2021 and ending on January 21, 2024, provided that the vesting of the option may be accelerated, in whole or in part, based on the achievement of certain pre-established company performance criteria, but in no event prior to January 21, 2021. /s/ Jason Duncan 2020-01-23